NovoCure (NVCR) Expected to Post Quarterly Earnings on Thursday

NovoCure (NASDAQ:NVCR) is expected to issue its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to announce earnings of ($0.2349) per share and revenue of $182.28 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

NovoCure Stock Down 1.9%

NASDAQ NVCR opened at $14.40 on Tuesday. The stock has a fifty day simple moving average of $16.15 and a 200-day simple moving average of $14.80. The company has a current ratio of 2.89, a quick ratio of 2.70 and a debt-to-equity ratio of 0.58. NovoCure has a twelve month low of $9.82 and a twelve month high of $21.45.

Analyst Ratings Changes

NVCR has been the topic of a number of recent analyst reports. HC Wainwright set a $32.00 target price on shares of NovoCure in a research report on Friday, July 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NovoCure in a research report on Thursday, August 27th. Zacks Research upgraded shares of NovoCure from a “strong sell” rating to a “hold” rating in a research report on Friday, July 24th. JPMorgan Chase & Co. initiated coverage on shares of NovoCure in a research note on Monday, July 13th. They issued a “neutral” rating and a $17.00 price target on the stock. Finally, Wedbush upped their price objective on shares of NovoCure from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $21.20.

About NovoCure

NovoCure Ltd. (NASDAQ: NVCR) is an oncology company that develops and commercializes therapies based on Tumor Treating Fields (TTFields), low-intensity electric fields designed to disrupt the division of cancer cells. Its treatments are delivered through portable, wearable devices used alongside other cancer therapies.

The company’s principal products include Optune Gio for certain adults with glioblastoma and Optune Lua for adults with unresectable, locally advanced or metastatic pleural mesothelioma and certain forms of metastatic non-small cell lung cancer.